Yile Wang

Cancer cell-selective ectopic expression of CD20 as an antigen enables rituximab repurposing for solid tumor immunotherapy

This paper demonstrates a strategy to repurpose rituximab for solid tumors by selectively expressing CD20 on cancer cells, enhancing NK cell-mediated cytotoxicity and showing high specificity and safety in multiple models.

A novel immunogene therapy to cancer with high tumor selectivity and safety

This paper develops a novel immunogene therapy that selectively targets cancer cells to enhance immune responses while minimizing toxicity to healthy tissues.